RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Mar 18, 2024 | Sale | $5.04 | 9,211 | 46,446 | 167,550 | Mar 19, 2024, 06:45 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Mar 15, 2024 | Option Exercise | $5.30 | 2,967 | 15,740 | 176,761 | Mar 19, 2024, 06:45 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | CLO & GC | Mar 15, 2024 | Option Exercise | $5.30 | 3,269 | 17,342 | 145,940 | Mar 19, 2024, 06:44 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | CLO & GC | Mar 18, 2024 | Sale | $5.04 | 8,125 | 40,971 | 137,815 | Mar 19, 2024, 06:44 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 15, 2024 | Option Exercise | $5.30 | 3,822 | 20,276 | 202,027 | Mar 19, 2024, 06:44 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 18, 2024 | Sale | $5.04 | 9,361 | 47,204 | 192,666 | Mar 19, 2024, 06:44 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Mar 15, 2024 | Option Exercise | $5.30 | 20,533 | 108,928 | 1,012,163 | Mar 19, 2024, 06:43 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Mar 06, 2024 | Buy | $6.98 | 30,000 | 209,400 | 1,015,468 | Mar 08, 2024, 04:33 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Dec 31, 2023 | Option Exercise | $7.47 | 264 | 1,972 | 157,618 | Jan 03, 2024, 04:50 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Dec 31, 2023 | Option Exercise | $7.47 | 264 | 1,972 | 914,718 | Jan 03, 2024, 04:47 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Dec 15, 2023 | Option Exercise | $8.08 | 4,712 | 38,073 | 157,354 | Dec 18, 2023, 04:32 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Sep 06, 2023 | Sale | $17.06 | 11,000 | 187,704 | 44,066 | Sep 07, 2023, 05:37 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Sep 05, 2023 | Sale | $17.81 | 23,853 | 424,920 | 55,066 | Sep 07, 2023, 05:37 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Aug 11, 2023 | Option Exercise | $18.91 | 11,215 | 212,076 | 91,301 | Aug 15, 2023, 04:16 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Aug 11, 2023 | Option Exercise | $18.91 | 9,592 | 181,385 | 78,919 | Aug 15, 2023, 04:15 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Aug 11, 2023 | Option Exercise | $18.91 | 8,901 | 168,318 | 162,066 | Aug 15, 2023, 04:15 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Aug 11, 2023 | Option Exercise | $18.91 | 48,064 | 908,890 | 914,454 | Aug 15, 2023, 04:15 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Aug 03, 2023 | Sale | $22.57 | 26,279 | 593,151 | 840,375 | Aug 04, 2023, 05:07 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2023 | Option Exercise | $15.61 | 769 | 12,001 | 81,597 | Jul 05, 2023, 09:11 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jul 03, 2023 | Sale | $25.04 | 1,701 | 42,593 | 79,896 | Jul 05, 2023, 09:11 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Jun 30, 2023 | Option Exercise | $15.61 | 1,000 | 15,606 | 148,347 | Jul 05, 2023, 09:11 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Jun 30, 2023 | Option Exercise | $15.61 | 1,000 | 15,606 | 892,933 | Jul 05, 2023, 09:11 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Jul 03, 2023 | Sale | $24.94 | 26,279 | 655,333 | 866,654 | Jul 05, 2023, 09:11 PM |
RVNC | | Revance Therapeutics, Inc. | Kolaja Carey OConnor | Director | Jun 15, 2023 | Sale | $23.18 | 5,000 | 115,900 | 19,061 | Jun 20, 2023, 04:25 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Jun 09, 2023 | Sale | $30.82 | 5,000 | 154,096 | 147,347 | Jun 13, 2023, 08:09 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Jun 09, 2023 | Sale | $30.72 | 31,279 | 960,928 | 891,933 | Jun 13, 2023, 08:09 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 01, 2023 | Sale | $30.57 | 2,701 | 82,570 | 81,328 | Jun 05, 2023, 06:06 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 02, 2023 | Sale | $31.00 | 500 | 15,500 | 80,828 | Jun 05, 2023, 06:06 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | May 15, 2023 | Sale | $34.55 | 21,401 | 739,338 | 69,165 | May 16, 2023, 08:29 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | May 15, 2023 | Sale | $34.55 | 21,401 | 739,338 | 84,029 | May 16, 2023, 08:29 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | May 15, 2023 | Sale | $34.55 | 70,447 | 2,433,726 | 923,212 | May 16, 2023, 08:29 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | May 15, 2023 | Sale | $34.55 | 21,015 | 726,003 | 152,347 | May 16, 2023, 08:29 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | May 01, 2023 | Sale | $31.70 | 3,201 | 101,472 | 63,081 | May 02, 2023, 04:01 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Apr 03, 2023 | Sale | $32.15 | 3,201 | 102,912 | 66,282 | Apr 04, 2023, 04:24 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Mar 15, 2023 | Option Exercise | $30.65 | 5,341 | 163,702 | 818,010 | Mar 17, 2023, 03:22 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 15, 2023 | Option Exercise | $30.65 | 3,739 | 114,600 | 69,483 | Mar 17, 2023, 03:21 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Mar 15, 2023 | Option Exercise | $30.65 | 7,330 | 224,664 | 48,217 | Mar 17, 2023, 03:21 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Mar 15, 2023 | Option Exercise | $30.65 | 2,967 | 90,939 | 120,967 | Mar 17, 2023, 03:21 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Mar 09, 2023 | Sale | $31.59 | 18,496 | 584,220 | 55,547 | Mar 09, 2023, 09:46 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 09, 2023 | Sale | $31.59 | 18,517 | 584,884 | 73,222 | Mar 09, 2023, 09:46 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Mar 09, 2023 | Sale | $31.59 | 21,508 | 679,358 | 123,934 | Mar 09, 2023, 09:45 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Mar 09, 2023 | Sale | $31.59 | 70,390 | 2,223,360 | 823,351 | Mar 09, 2023, 09:45 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Mar 01, 2023 | Sale | $33.50 | 3,201 | 107,234 | 49,390 | Mar 02, 2023, 09:25 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Feb 15, 2023 | Option Exercise | $33.21 | 2,766 | 91,859 | 93,046 | Feb 16, 2023, 08:29 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2023 | Option Exercise | $33.21 | 2,085 | 69,243 | 52,591 | Feb 16, 2023, 08:28 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 01, 2023 | Sale | $34.60 | 3,201 | 110,755 | 54,676 | Feb 02, 2023, 09:38 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jan 20, 2023 | Sale | $31.00 | 1,000 | 31,000 | 57,877 | Jan 23, 2023, 05:35 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jan 09, 2023 | Sale | $27.16 | 3,701 | 100,525 | 60,877 | Jan 10, 2023, 08:06 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2022 | Option Exercise | $12.18 | 645 | 7,856 | 62,578 | Jan 03, 2023, 04:29 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Dec 31, 2022 | Option Exercise | $12.18 | 605 | 7,369 | 95,812 | Jan 03, 2023, 04:28 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Dec 31, 2022 | Option Exercise | $12.18 | 605 | 7,369 | 718,092 | Jan 03, 2023, 04:28 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2022 | Option Exercise | $21.50 | 1,557 | 33,476 | 61,933 | Dec 16, 2022, 04:12 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Dec 15, 2022 | Option Exercise | $21.50 | 2,916 | 62,694 | 95,207 | Dec 16, 2022, 04:11 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Oct 13, 2022 | Option Exercise | $26.97 | 49,274 | 1,328,920 | 717,487 | Oct 14, 2022, 07:02 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Sep 14, 2022 | Sale | $27.07 | 11,000 | 297,798 | 31,694 | Sep 16, 2022, 04:55 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Jun 30, 2022 | Option Exercise | $11.75 | 1,000 | 11,747 | 766,761 | Jul 05, 2022, 06:15 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Jun 30, 2022 | Option Exercise | $11.75 | 1,000 | 11,747 | 98,123 | Jul 05, 2022, 06:15 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2022 | Option Exercise | $11.75 | 965 | 11,336 | 63,490 | Jul 05, 2022, 06:15 PM |
RVNC | | Revance Therapeutics, Inc. | Joshi Abhay | COO, President of R&D | Mar 15, 2022 | Option Exercise | $15.79 | 2,607 | 41,165 | 120,708 | Mar 17, 2022, 05:56 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | Chief Executive Officer | Mar 15, 2022 | Option Exercise | $15.79 | 3,304 | 52,170 | 765,761 | Mar 17, 2022, 05:54 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Mar 15, 2022 | Option Exercise | $15.79 | 5,110 | 80,687 | 44,923 | Mar 17, 2022, 05:52 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | Director | Mar 15, 2022 | Option Exercise | $15.79 | 1,372 | 21,664 | 94,091 | Mar 17, 2022, 05:50 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | Chief Financial Officer | Mar 15, 2022 | Option Exercise | $15.79 | 2,607 | 41,165 | 62,525 | Mar 17, 2022, 05:48 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Mar 15, 2022 | Option Exercise | $15.79 | 1,835 | 28,975 | 97,123 | Mar 17, 2022, 05:43 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Feb 15, 2022 | Option Exercise | $13.35 | 2,429 | 32,427 | 99,253 | Feb 17, 2022, 08:54 PM |
RVNC | | Revance Therapeutics, Inc. | Joshi Abhay | COO, President, R&D | Feb 15, 2022 | Option Exercise | $13.35 | 5,053 | 67,458 | 126,217 | Feb 17, 2022, 08:51 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2022 | Option Exercise | $13.35 | 2,924 | 39,035 | 65,815 | Feb 17, 2022, 08:49 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2021 | Option Exercise | $13.87 | 404 | 5,604 | 68,056 | Jan 04, 2022, 08:58 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2021 | Option Exercise | $15.92 | 1,556 | 24,772 | 67,652 | Dec 17, 2021, 05:31 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | President | Dec 15, 2021 | Option Exercise | $15.92 | 513 | 8,167 | 101,387 | Dec 17, 2021, 05:29 PM |
RVNC | | Revance Therapeutics, Inc. | Russell Angus C. | Director | Dec 13, 2021 | Buy | $15.74 | 6,400 | 100,741 | 26,913 | Dec 15, 2021, 08:17 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Dec 03, 2021 | Buy | $14.43 | 30,000 | 432,876 | 95,463 | Dec 06, 2021, 08:34 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO | Nov 29, 2021 | Buy | $12.90 | 40,000 | 515,924 | 110,913 | Nov 29, 2021, 09:24 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO & President | Oct 13, 2021 | Option Exercise | $23.08 | 42,096 | 971,576 | 769,065 | Oct 15, 2021, 08:00 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Sep 27, 2021 | Sale | $30.00 | 1,675 | 50,250 | 47,804 | Sep 28, 2021, 09:23 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Aug 15, 2021 | Option Exercise | $26.02 | 4,949 | 128,773 | 74,827 | Aug 17, 2021, 06:20 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Aug 16, 2021 | Sale | $26.34 | 9,364 | 246,659 | 65,463 | Aug 17, 2021, 06:20 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Jul 28, 2021 | Sale | $30.00 | 34,332 | 1,029,960 | 321,611 | Jul 30, 2021, 08:57 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Jul 28, 2021 | Sale | $30.15 | 20,000 | 603,000 | 154,302 | Jul 30, 2021, 08:57 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Jul 26, 2021 | Sale | $29.72 | 55,382 | 1,645,953 | 355,943 | Jul 28, 2021, 09:48 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | Chief Commercial Officer | Jun 30, 2021 | Option Exercise | $24.09 | 882 | 21,246 | 65,980 | Jul 02, 2021, 07:56 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Jun 30, 2021 | Option Exercise | $24.09 | 446 | 10,744 | 69,208 | Jul 02, 2021, 07:53 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO & President | Jun 30, 2021 | Option Exercise | $24.09 | 882 | 21,246 | 811,161 | Jul 02, 2021, 07:52 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | Chief Commercial Officer | Apr 15, 2021 | Option Exercise | $28.16 | 411 | 11,574 | 65,098 | Apr 16, 2021, 08:17 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Apr 05, 2021 | Sale | $28.28 | 2 | 57 | 411,325 | Apr 06, 2021, 07:41 PM |
RVNC | | Revance Therapeutics, Inc. | Moxie Dwight | SVP, GC & Secretary | Mar 15, 2021 | Option Exercise | $27.73 | 2,881 | 79,890 | 49,479 | Mar 17, 2021, 07:29 PM |
RVNC | | Revance Therapeutics, Inc. | Joshi Abhay | COO, President, R&D | Mar 15, 2021 | Option Exercise | $27.73 | 1,354 | 37,546 | 128,368 | Mar 17, 2021, 07:27 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Mar 04, 2021 | Sale | $25.43 | 33,119 | 842,216 | 411,327 | Mar 05, 2021, 08:10 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Feb 15, 2021 | Option Exercise | $28.97 | 2,657 | 76,973 | 70,735 | Feb 19, 2021, 08:15 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | Chief Commercial Officer | Feb 15, 2021 | Option Exercise | $28.97 | 2,410 | 69,818 | 67,644 | Feb 19, 2021, 08:13 PM |
RVNC | | Revance Therapeutics, Inc. | Joshi Abhay | COO, President, R&D | Feb 15, 2021 | Option Exercise | $28.97 | 4,848 | 140,447 | 132,603 | Feb 19, 2021, 08:10 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Feb 01, 2021 | Sale | $25.95 | 33,119 | 859,438 | 444,446 | Feb 03, 2021, 08:13 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 31, 2020 | Option Exercise | $21.36 | 493 | 10,531 | 48,799 | Jan 04, 2021, 08:02 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Dec 30, 2020 | Sale | $27.82 | 33,119 | 921,212 | 477,565 | Jan 04, 2021, 08:01 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | Chief Commercial Officer | Dec 31, 2020 | Option Exercise | $21.36 | 348 | 7,433 | 45,299 | Jan 04, 2021, 07:59 PM |
RVNC | | Revance Therapeutics, Inc. | Schilke Tobin | CFO | Dec 15, 2020 | Option Exercise | $26.75 | 1,556 | 41,623 | 48,306 | Dec 22, 2020, 08:39 PM |
RVNC | | Revance Therapeutics, Inc. | Sjuts Dustin S | Chief Commercial Officer | Dec 15, 2020 | Option Exercise | $26.75 | 562 | 15,034 | 44,951 | Dec 22, 2020, 08:37 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Nov 30, 2020 | Sale | $23.85 | 33,119 | 789,888 | 510,684 | Dec 02, 2020, 08:55 PM |
RVNC | | Revance Therapeutics, Inc. | Rankin Aubrey | President, Innovation & Tech | Oct 29, 2020 | Sale | $26.15 | 33,119 | 865,949 | 543,803 | Oct 30, 2020, 08:24 PM |
RVNC | | Revance Therapeutics, Inc. | Foley Mark J | CEO & President | Oct 13, 2020 | Option Exercise | $27.62 | 66,106 | 1,825,848 | 769,564 | Oct 15, 2020, 06:57 PM |